You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Colorectal cancer

Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

  • Technology appraisal guidance
  • Reference number: TA118
  • Published:  24 January 2007
  • Last updated:  01 January 2012
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Guidance
  • 2 Clinical need and practice
  • 3 The technologies
  • 4 Evidence and interpretation
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Related guidance
  • 8 Review of guidance
  • Appendix A. Appraisal Committee members and NICE project team
  • Appendix B. Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance

7 Related guidance

7.1 NICE has issued the following related guidance.

  • Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. NICE technology appraisal guidance 93 (2005).[Replaced by NICE clinical guideline 131]

  • Improving outcomes in colorectal cancers: manual update. NICE cancer service guidance (2004).

  • Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer. NICE technology appraisal guidance 61 (2003).


Next page 8 Review of guidance Previous page 6 Recommendations for further research